Phesi
Phesi CEO warns phase 3 trial failures loom as sponsors overlook real-world data and overcrowd investigator sites
Boston, US. 9 July, 2025. Dr. Gen Li, CEO of Phesi, a global provider of patient-centric data analytics, has warned the clinical development industry that phase 3 trials in multiple indications are heading for avoidable failure. Overly complex trial design, coupled with a lack of real-world data integration, is leading to investigator site saturation and...
Phesi launches self-service Investigator Site Profiler solution to enhance precision of investigator site selection
Solution benefits clinical development and medical affairs groups – eliminating 20%-30% of investigator sites where there isn’t sufficient data to ensure performance 2 April 2025 -- Massachusetts, US -- Phesi, a global provider of patient-centric data analytics, has launched its self-service Investigator Site Profiler solution. Leveraging the data lake from Phesi’s award-winning AI-powered Trial Accelerator™...
Phesi announces AI-driven Trial Accelerator platform hits new milestone with data from 132 million patients
Latest version of Trial Accelerator™ incorporates new AI capabilities and product features to unlock a patient-centric approach to trial design and implementation 29 January 2025 -- Boston, US -- Phesi, a global provider of patient-centric data analytics, has launched Version 2 of its award-winning Trial Accelerator™ platform, with enhanced AI capabilities and new features for...
Phesi launches Investigator Site Profile solution, enabling sponsors to eliminate non-active, non-enrolling trial sites
AI-powered analysis of 120m patient profiles and 600,000 global investigator records delivers deep visibility into investigator site expertise, experience and clinical relevance 26 September 2024 -- Massachusetts, US -- Phesi, a leading clinical development analytics company, has launched a self-service Investigator Site Profile solution designed to eliminate the non-active and non-enrolling investigator sites that development...
New Phesi proof of concept demonstrates potential of AI-powered digital twins to replace external control arms in clinical trials
Study published in Bone Marrow Transplantation uses real-world clinical data to create virtual digital twin cohorts instead of placebo and standard-of-care comparator arms 20 June 2024 -- Massachusetts, US -- Phesi, a leading clinical development analytics company, has today published new research in the journal Bone Marrow Transplantation (BMT-Nature). The study demonstrates that AI-powered digital...
Global oncology trial investigator sites increase by half in five years, finds new Phesi analysis
China flagged as significant contributor to growth, but poor investigator selection is causing trial failures 23 May 2024 -- Massachusetts, US -- Phesi, a leading clinical development analytics company, has released a new analysis of global oncology trial investigator sites ahead of attending ASCO 2024 – the American Society of Clinical Oncology’s annual meeting. Using...
Phesi launches predictive Patient Burden Score to improve trial efficiency, patient experience and investigator site performance
Latest real-world metric in Phesi’s AI-driven Trial Accelerator quantifies patient burden to unlock a patient-centric approach to trial design and implementation 7 May 2024 -- Boston, US -- Phesi, a patient-centric data analytics company, has today announced it has enhanced its AI-driven Trial Accelerator platform with the addition of the Patient Burden Score. The Patient...
Phesi releases 2023 analysis of clinical development; breast cancer remains most studied disease area for third year
Annual analysis of data from 95 million patients shows signs of post-pandemic recovery for clinical development industry, but trial cancellation rates at phase 2 remain high 16 January 2024 -- Massachusetts, US -- Phesi, a global provider of patient-centric data analytics, has today released the results of its annual global analysis of all clinical trials conducted...
Phesi launches Health Check and Trial Rescue Service to save at-risk trials and bring drugs to market faster
New free of charge service will offer insights in under ten days to sponsors conducting clinical trials in any indication, identifying potential “zombie trials” and providing actionable recommendations for failing trials 12 October 2023 -- Massachusetts, US -- Today, global provider of patient-centric data software and services Phesi announces the launch of its new Health...
Phesi and Krystelis collaborate to launch new Diversity, Equity and Inclusion Data Service for clinical development
New Diversity, Equity, and Inclusion (DEI) Data Service will harness data from 70 million patients to enable sponsors to create more diverse trials, reduce protocol amendments and meet new FDA regulations 6 September 2023 -- Boston, US -- Phesi, a global provider of patient-centric data software and services, today announces its partnership with Krystelis, a...
